| Allergic rhinitis (disorder)
Rayos vs Dymista
Side-by-side clinical, coverage, and cost comparison for allergic rhinitis (disorder).Deep comparison between: Rayos vs Dymista with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDymista has a higher rate of injection site reactions vs Rayos based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Dymista but not Rayos, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rayos
Dymista
At A Glance
Oral
Daily
Corticosteroid
Nasal spray
Twice daily
H1 antagonist/corticosteroid combination
Indications
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
- Allergic rhinitis (disorder)
Dosing
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Allergic rhinitis (disorder) 1 spray (137 mcg azelastine hydrochloride and 50 mcg fluticasone propionate) per nostril twice daily, by nasal route only.
Contraindications
- Known hypersensitivity to prednisone or any excipient
- Hypersensitivity to azelastine hydrochloride, fluticasone propionate, or any other ingredient of DYMISTA (including anaphylaxis)
Adverse Reactions
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Most common (>=2%) Dysgeusia, headache, epistaxis
Serious Somnolence, epistaxis, nasal ulceration, nasal septal perforation, impaired wound healing, Candida albicans infection, glaucoma, cataracts, immunosuppression, hypercorticism, adrenal suppression
Postmarketing Atrial fibrillation, palpitations, increased heart rate, blurred vision, cataracts, glaucoma, increased intraocular pressure, nausea, vomiting, anaphylaxis, growth suppression, disturbance or loss of smell and/or taste, dizziness, urinary retention, bronchospasm, dyspnea, nasal septal perforation, angioedema, hypertension
Pharmacology
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
DYMISTA combines azelastine hydrochloride, a histamine H1-receptor antagonist (phthalazinone derivative), and fluticasone propionate, a synthetic trifluorinated corticosteroid that exerts anti-inflammatory activity on multiple cell types (mast cells, eosinophils, macrophages, lymphocytes) and mediators (histamine, leukotrienes, cytokines) involved in allergic rhinitis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
Dymista
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Dymista
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Dymista
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rayos.
No savings programs available for Dymista.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DymistaView full Dymista profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.